Khalid Ali Shah

This inventor holds 38 USPTO granted patents and 25 published patent applications, plus 2 CIPO patents and 12 EPO patents, primarily in Cancer Treatment. Top assignees: Exelixis, Inc., The General Hospital Corporation, Array Biopharma Inc.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Khalid Ali Shah. Retrieved from https://idiyas.com/inventor/khalid-ali-shah

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 38 (Patent Applications = 25)

% Patents Active = 94.7

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 12 (Patent Applications = 21)

Average Co-Inventor Count = 1.9

ph-index = 9

Forward Citations = 298(Granted Patents)

Location History:

Calgary, CA (2013)
Houston, TX (US) (2016)
South San Francisco, CA (US) (2017 - 2020)
Andover, MA (US) (2016 - 2024)
Half Moon Bay, CA (US) (2017 - 2024)

Company Filing History:

The General Hospital Corporation

The Brigham and Women's Hospital, Inc.

patents

5. 1 out of 74

Clearwater International LLC

patents

6. 3 out of 834,570

Other

patents

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Kinase Inhibitor

Oncolytic Virus Therapy

Quinoline Compounds

Tumor Cell Killers

Pharmaceutical Compositions

C-Met Modulator

Liquid Dosage Forms

Glioblastoma Treatment

Biodegradable Matrix

Multimodal TRAIL Molecules

Corrosion Inhibitor Systems

Stem Cells

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679809 - Crystalline forms and salt forms of a kinase inhibitor (2026-07-14),

2. 12527821 - COMPOSITIONS AND METHODS RELATED TO TUMOR CELL KILLERS AND VACCINES (2026-01-20),

3. 12497367 - Processes for the preparation of a kinase inhibitor (2025-12-16),

4. 12486233 - Crystalline Solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2025-12-02),

5. 12227481 - Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2025-02-18),

6. 12128039 - Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds (2024-10-29),

7. 12017995 - Crystalline forms and salt forms of a kinase inhibitor (2024-06-25),

8. 12016882 - Method of treating glioblastoma multiforme (2024-06-25),

9. 12016854 - Liquid dosage forms to treat cancer (2024-06-25),

10. 11760726 - Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2023-09-19),

11. 11731941 - Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2023-08-22),

12. 11724986 - Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2023-08-15),

13. 11504362 - Liquid dosage forms to treat cancer (2022-11-22),

14. 11298349 - Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds (2022-04-12),

15. 11279675 - Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use (2022-03-22),

Sure, I can help you with that. Here is the article about inventor Khalid Ali Shah:

Title: Innovator Spotlight: Khalid Ali Shah from Houston, TX

Introduction:

Khalid Ali Shah, a prolific inventor based in Houston, Texas, is renowned for his groundbreaking work in the field of pharmaceuticals. With an impressive portfolio of 24 patents, Khalid has made significant contributions to the field of drug development and treatment.

Latest Patents:

Among his latest patents is the development of crystalline forms and salt forms of a kinase inhibitor. This invention revolves around solid polymorphs of the free base and salts of Compound 1, a c-Met inhibitor. Additionally, Khalid has also patented a liquid pharmaceutical composition comprising cabozantinib to treat advanced urothelial cancer or renal cell carcinoma.

Career Highlights:

Having worked with esteemed companies such as Exelixis, Inc. and Array Biopharma Inc., Khalid Ali Shah has garnered invaluable experience in the pharmaceutical industry. His innovative research and development have led to the creation of novel drug formulations with the potential to revolutionize cancer treatment.

Collaborations:

During his career, Khalid has collaborated closely with industry experts and researchers. Notable coworkers include Jo Ann Wilson and Alisha B. Arrigo, with whom Khalid has shared his knowledge and expertise to drive advancements in drug discovery and development.

Conclusion:

In conclusion, Khalid Ali Shah stands as a trailblazer in the field of pharmaceutical innovation, with a rich history of patents and contributions to the advancement of cancer treatment. His relentless pursuit of scientific excellence has positioned him as a key figure in the industry, shaping the future of healthcare through groundbreaking inventions.

Profile summary based on public USPTO records.